MedTrace Logo

The Interaction Between Measles and DTP Vaccination

NCT02710045 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2019-01-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate for the broad immunological effects of administering measles vaccine (MV) and diphtheria-tetanus-whole cell pertussis vaccine (DTP) to 9 month old Gambian infants, either alone or together. Effects on vaccine-specific immune responses, innate immunity, and immune memory were studied. The hypothesis is that when MV and DTP are given together there will be more inflammation and this will interfere with generation of immunity to the vaccine and to other non-vaccine related stimuli.

Conditions

  • Non-target Heterologous Effects of Vaccines
  • Vaccine Interactions

Interventions

BIOLOGICAL

Measles Vaccine at 9 months of age

Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age

BIOLOGICAL

DTP Vaccine at 9 months of age

Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age

BIOLOGICAL

Measles Vaccine at 18 months of age

Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age

Sponsors & Collaborators

  • Medical Research Council Unit, The Gambia

    lead OTHER

Principal Investigators

  • Katie L Flanagan, PhD · University of Tasmania, Australia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
16 Weeks
Max Age
22 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-03-31
Completion
2011-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02710045 on ClinicalTrials.gov